Dr. Rudresha AH

Dr. Rudresha has contributed numerous publications in national and international journals. Some of them include:

• Jacob, L. A., Choudhary, S. K., Babu, M. C. S., N, L. K., Rudresha, A. H., Rajeev, L. K., Saldanha, S. C., Hegde, A., & M, V. B. (2024). Unmasking Infection Risks in Multiple Myeloma: Insights from a Retrospective Analysis. Indian Journal of Hematology and Blood Transfusion/Indian Journal of Hematology and Blood Transfusion.
• Choudhary, A., Jacob, L. A., Babu, S., KN, L., AH, R., LK, R., Saldanha, S., & Begum, T. (2024). Mortality audit of cancer patients in the Department of Medical Oncology at a tertiary cancer care center in South India. Cur?us.
• Lokesh, K. N., Hegde, A. R., Babu, M. C. S., Rudresha, A. H., Rajeev, L. K., Saldanha, S. C., Choudhary, A., & Jacob, L. A. (2023). Impact of body mass index on pathological complete response following neoadjuvant chemotherapy in locally advanced breast cancer – a South Indian single-institute experience. Oncology Journal of India, 7(3), 45–49.
• Mc, S. B., Choudhary, A., Jacob, L. A., Kn, L., Ah, R., Lk, R., Saldanha, S., Sankar, K., & Amritham, U. (2023). “Triple Negative Breast Cancer: Experience at a Tertiary Cancer Care Center in South India.” International Journal of Scientific Research, 42–45.
• Babbar, P., Haleshappa, R. A., Dasappa, L., Jacob, L., Babu, S., Nagendrappa, L. K., Krishnappa, R. L., & Saldanha, S. (2021). 915P Carboplatin in combination with three weekly paclitaxels as first-line therapy in patients with recurrent/metastatic head and neck cancers: A regional cancer center experience. Annals of Oncology, 32, S809.